Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

Ogbe A. et al, (2021), Nat Commun, 12

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Hall VJ. et al, (2021), The Lancet

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.

Townsend A. et al, (2021), Nat Commun, 12

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Zhou D. et al, (2021), Cell

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

Supasa P. et al, (2021), Cell

Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection.

Frost JN. et al, (2021), Med (N Y), 2, 164 - 179.e12

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288

Role of Burkholderia pseudomallei-Specific IgG2 in Adults with Acute Melioidosis, Thailand.

Chaichana P. et al, (2021), Emerg Infect Dis, 27, 463 - 470

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Ewer KJ. et al, (2021), Nat Med, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M. et al, (2021), Lancet, 397, 99 - 111

Mapping routine measles vaccination in low- and middle-income countries.

Local Burden of Disease Vaccine Coverage Collaborators None., (2021), Nature, 589, 415 - 419

Geospatial mapping of the global prevalence of antimicrobial resistant Salmonella Typhi and Paratyphi A isolates

Browne A. et al, (2020), INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 101, 28 - 28

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

National SARS-CoV-2 Serology Assay Evaluation Group None., (2020), Lancet Infect Dis, 20, 1390 - 1400

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.

Peng Y. et al, (2020), Nat Immunol, 21, 1336 - 1345

Five insights from the Global Burden of Disease Study 2019.

GBD 2019 Viewpoint Collaborators None., (2020), Lancet, 396, 1135 - 1159

Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Demographics Collaborators None., (2020), Lancet, 396, 1160 - 1203

Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Risk Factors Collaborators None., (2020), Lancet, 396, 1223 - 1249

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Diseases and Injuries Collaborators None., (2020), Lancet, 396, 1204 - 1222

Load More

1
2
3
4
5